SEC Form 4 · accession 0001209191-17-046001
Dare Bioscience, Inc. · DARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Susan L. Kelley
Director
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 5:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401914
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2,F1,F3 | $6.56 | Jul 19, 2017 | A | 2,000 | A | — | Jul 19, 2027 | Common Stock | 2,000 | 2,000 | D |
Explanation of responses
- F1The exercise price reported reflects the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017.
- F2Dr. Kelley was awarded options to purchase shares of the Corporation's common stock in connection with her service as a member of the Board of Directors (the "Director Options") pursuant to the Corporation's 2014 Stock Incentive Plan.
- F3The Director Options will vest in equal annual installments over a three-year period measured from the date of grant, subject to Dr. Kelley's continued service to the Corporation and will become exercisable in full upon a change of control of the Corporation.